These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17115005)

  • 1. [Do dendritic cells modified with retroviral vectors carrying cytokine genes become a therapeutic tool?].
    Szyda A; Rossowska J; Pajtasz-Piasecka E; Duś D
    Postepy Hig Med Dosw (Online); 2006; 60():552-62. PubMed ID: 17115005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.
    Chen YZ; Yao XL; Tabata Y; Nakagawa S; Gao JQ
    Clin Dev Immunol; 2010; 2010():565643. PubMed ID: 21197274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells as vectors for immunotherapy of cancer.
    Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
    Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor vaccines and peptide-loaded dendritic cells (DCs)].
    Schummer V; Flindt S; Hinz T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1254-8. PubMed ID: 26349562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization delivered by lentiviral vectors for cancer and infectious diseases.
    Hu B; Tai A; Wang P
    Immunol Rev; 2011 Jan; 239(1):45-61. PubMed ID: 21198664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically modified dendritic cell-based cancer vaccines.
    Bubeník J
    Folia Biol (Praha); 2001; 47(5):153-5. PubMed ID: 11686430
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetically engineered dendritic cell-based cancer vaccines (review).
    Bubeník J
    Int J Oncol; 2001 Mar; 18(3):475-8. PubMed ID: 11179474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
    Cervantes-Barragan L; Züst R; Maier R; Sierro S; Janda J; Levy F; Speiser D; Romero P; Rohrlich PS; Ludewig B; Thiel V
    mBio; 2010 Sep; 1(4):. PubMed ID: 20844609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-modified dendritic cells for use in tumor vaccines.
    Kirk CJ; Mulé JJ
    Hum Gene Ther; 2000 Apr; 11(6):797-806. PubMed ID: 10779157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
    Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
    Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines and immunotherapeutics for the treatment of malignant disease.
    Aldrich JF; Lowe DB; Shearer MH; Winn RE; Jumper CA; Kennedy RC
    Clin Dev Immunol; 2010; 2010():697158. PubMed ID: 20936120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of dendritic cell-based vaccines for cancer therapy.
    Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
    Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A focus on vaccination strategies.
    Woodland DL
    Viral Immunol; 2014 Nov; 27(9):421. PubMed ID: 25361209
    [No Abstract]   [Full Text] [Related]  

  • 16. mRNA-based dendritic cell vaccines.
    Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
    Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
    Goyvaerts C; Breckpot K
    J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.
    Schettini J; Mukherjee P
    Clin Dev Immunol; 2008; 2008():106321. PubMed ID: 19190769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene modification strategies to induce tumor immunity.
    Murphy A; Westwood JA; Teng MW; Moeller M; Darcy PK; Kershaw MH
    Immunity; 2005 Apr; 22(4):403-14. PubMed ID: 15845446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.